Are you testing for PD-L1 IHC expression in extensive stage small cell lung cancer who are planned to be treated with chemotherapy plus immunotherapy?

Are there subsets of patients who will not benefit with addition of first line immunotherapy?

Answer from: Medical Oncologist at Community Practice

Based on trial approved chemo-immunotherapy for ES-SCLC, it is not a requirement. IMpower33 (Atezo) and Caspian trial (durva).